The applicant in a class action against self-managed superfund provider Dixon Advisory wants to intervene in ASIC’s proceedings, which the company agreed to resolve for $7.2 million, saying any penalty in the case should be held by the court until the resolution of the class action.
IP Australia has won its appeal of a judge’s decision to allow four Aristocrat patents for its popular Lightning Link electronic poker machine to proceed to grant, with the Full Court finding the invention merely implemented an abstract idea on a computer and was not patentable.
A law firm that has filed seven class actions on behalf of casual coal mine workers is looking to discontinue two of those cases, after the High Court dealt them a serious blow by finding that those who work regular shifts are not entitled to paid leave and other entitlements under the Fair Work Act.
A judge has given the green light to expanded misconduct allegations in a shareholder class action against IOOF, including claims of insider trading and front-running.
The corporate regulator has taken MLC Limited to court, alleging the insurer’s failure to implement proper systems and controls over a more than 20 year period caused $17.5 million in harm to over a quarter million consumers.
Mayfair 101 director James Mawhinney is seeking disciplinary action against ASIC’s lawyers over a media release accusing him of breaching a 20-year ban on raising funds and which disclosed the regulator had asked a court to hold him in contempt.
A judge has indicated he will approve the ‘very low’ GetSwift class action settlement because the company appeared to be broke, but the law firm behind the case has been pulled up by the court for a previous costs estimate that has blown out by $3 million.
A judge has scolded Slater & Gordon and two Westpac subsidiaries for a “disgraceful” privilege spat in a class action over allegedly excessive superannuation fees that he said had “gone badly off the rails”.
Clyde & Co made an “inextricable” oversight in preparing an unpaid works claim, causing a Sydney-based sandstone excavator to lose millions of dollars, according to a cross claim in a case brought by the law firm for unpaid fees.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.